Cargando…

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

OBJECTIVES: Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimum dose regimen in this population has not been clearly studied. The CRO-VAX HCP study aims to investigate the early antibod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Favresse, Julien, Bayart, Jean-Louis, Mullier, François, Dogné, Jean-Michel, Closset, Mélanie, Douxfils, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:	Research Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106520/ https://www.ncbi.nlm.nih.gov/pubmed/33975007 http://dx.doi.org/10.1016/j.cmi.2021.05.004

Ejemplares similares

Antibody titres decline 3-month post-vaccination with BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
por: Favresse, Julien, et al.
Publicado: (2022)

Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19—BNT162b2 mRNA Vaccination
por: Catry, Emilie, et al.
Publicado: (2022)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature
por: Douxfils, Jonathan, et al.
Publicado: (2021)

Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity
por: Favresse, Julien, et al.
Publicado: (2022)

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Clinical performance evaluation of the Fluorecare® SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals
por: Bayart, Jean-Louis, et al.
Publicado: (2023)

Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant
por: Bayart, Jean-Louis, et al.
Publicado: (2022)

NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments
por: Gillot, Constant, et al.
Publicado: (2021)

Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity
por: Favresse, Julien, et al.
Publicado: (2022)

Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome
por: Gillot, Constant, et al.
Publicado: (2022)

Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects
por: Gillot, Constant, et al.
Publicado: (2021)

Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls
por: Evrard, Jonathan, et al.
Publicado: (2022)

Post-SARS-CoV-2 vaccination specific antibody decrease — Thresholds for determining seroprevalence and seroneutralization differ
por: Douxfils, Jonathan, et al.
Publicado: (2021)

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
por: Gressens, Simon B., et al.
Publicado: (2022)

Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection
por: Favresse, Julien, et al.
Publicado: (2021)

Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan
por: Saita, Mizue, et al.
Publicado: (2022)

Adverse events after BNT162b2 mRNA COVID-19 vaccination in health care workers and medical students in Japan
por: Namiki, Takahiro, et al.
Publicado: (2022)

Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination
por: Douxfils, Jonathan, et al.
Publicado: (2021)

Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels
por: Douxfils, Jonathan, et al.
Publicado: (2021)

Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis
por: Haguet, Hélène, et al.
Publicado: (2020)

Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults
por: Erice, Alejo, et al.
Publicado: (2022)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients
por: Saiag, Esther, et al.
Publicado: (2022)

Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination
por: Favresse, Julien, et al.
Publicado: (2021)

High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies
por: Mairesse, Antoine, et al.
Publicado: (2020)

Response to “Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases”
por: Lim, Ziying Vanessa, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
por: Douxfils, Jonathan, et al.
Publicado: (2014)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
por: Haguet, Hélène, et al.
Publicado: (2018)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

DIAPHRAGMATIC PARALYSIS FOLLOWING SECOND DOSE OF THE BNT162B2 MRNA COVID-19 VACCINE
por: PRUDENTI, JOHN A, et al.
Publicado: (2022)

SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study
por: Guijarro, Carlos, et al.
Publicado: (2021)

An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens
por: Gillot, Constant, et al.
Publicado: (2020)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection
por: Favresse, Julien, et al.
Publicado: (2023)

Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan
por: Kageyama, Takahiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gm8sbi359va1chpvhnfpbg8til